Group items tagged

There are 5.4 million individuals who self-identify as American Indian/Alaska Native (AI/AN) in the US, and there are 567 federally registered tribes. While characterized by many strengths and resiliencies, as a whole, AI/AN populations experience significant disparities compared to the general population across a range of health conditions and outcomes, including infant mortality, alcohol-related mortality, substance abuse, unintentional injury, homicide, suicide, depression, post-traumatic stress disorder, obesity, chronic kidney disease, asthma, diabetes, cardiovascular disease, selected cancers, and other chronic diseases. Premature death rates, while decreasing in other US racial/ethnic minority populations over the past 15 years, are increasing among AI/AN populations. However, the examination of data on AI/AN populations in aggregate may obscure the significant heterogeneity within the AI/AN population due to tribal affiliation, geographic region, and other factors. For example, gastric cancers affect AI/AN populations in different parts of the country at different rates ranging from 6.1/100,00 in the Eastern US to 24.5/100,000 in Alaska. At the same time, national survey and epidemiological studies often do not report data on AI/AN populations because the numbers are too small or AI/AN individuals are folded into the highly heterogeneous "Other" category, thus not available to interpret any health outcomes specific for AI/AN populations. For these reasons, there is a critical need to build a more comprehensive evidence base regarding the health of AI/AN populations.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will host a pre-application webinar on November 9, 2020 from 3:00 PM - 4:00 PM EST (Eastern Standard Time) for the Funding Opportunity Announcement (FOA) RFA-DK-20-021 "Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)" for those interested in learning more about the FOA. The webinar is open to all prospective applicants, although participation in the webinar is not required to submit an application to RFA-DK-20-021.

The American Society of Nephrology fights to prevent, treat, and cure kidney diseases by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. As part of this mission, the ASN Foundation is accepting applications for its William and Sandra Bennett Clinical Scholars Program. The goal of the program is to help produce the next generation of clinician educators by enabling applicants to improve their teaching skills through the acquisition of education tools and by supporting aspiring nephrology educators to conduct a project that advances an aspect of nephrology education and teaching.

NineSigma, representing a Japanese pharmaceutical company, seeks a drug seeds for developing novel, oral, low-molecular weight, drugs for treating chronic kidney disease (CKD).

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications for innovative research projects examining the basic and clinical aspects of HIV infection, treatment, and long-term sequelae as they relate to the mission of the Division of Kidney, Urologic and Hematologic Diseases within NIDDK (KUH/NIDDK).

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications for innovative research projects examining the basic and clinical aspects of HIV infection, treatment, and long-term sequelae as they relate to the mission of the Division of Kidney, Urologic and Hematologic Diseases within NIDDK (KUH/NIDDK).

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The over-arching goal of this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce.  NIDDK's Short-Term Research Experience for Underrepresented Persons (STEP-UP) provides funding to research institutions to provide for a national summer research experience program for both high school and undergraduate students for eight to ten weeks.  STEP-UP seeks to facilitate exposure opportunities for students from diverse backgrounds underrepresented in biomedical research on a national basis, including individuals from disadvantaged backgrounds, individuals from underrepresented racial and ethnic groups and individuals with disabilities.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) R25 program is to support educational activities that enhance the diversity of the biomedical, behavioral and clinical research workforce. NIDDK's Short-Term Research Experience for Underrepresented Persons (STEP-UP) provides funding to research institutions to provide for a national summer research experience program for both high school and undergraduate students for eight to ten weeks. STEP-UP seeks to facilitate exposure opportunities for students from diverse backgrounds underrepresented in biomedical research on a national basis, including individuals from disadvantaged backgrounds, individuals from underrepresented racial and ethnic groups and individuals with disabilities. To accomplish the stated goal, this FOA will support creative educational activities with a primary focus on Research Experiences and Mentoring Activities

The National Institute of Allergy and Infectious Diseases (NIAID) solicits applications from single institutions and consortia of institutions to participate in the Nonhuman Primate Transplantation Tolerance Cooperative Study Group (NHPCSG) program. The NHPCSG is a multi-center, cooperative program for research on nonhuman primate (NHP) models of kidney, pancreatic islet, heart, and lung transplantation. The goals of the NHPCSG are to evaluate the preclinical safety and efficacy of existing and newly developed immune tolerance induction regimens and to elucidate the underlying mechanisms of the induction, maintenance, and/or loss of tolerance in these models. The long-range goal of this program is to develop and evaluate immune tolerance induction regimens that will result in enhanced long-term graft survival in clinical transplantation.

The Oxalosis and Hyperoxaluria Foundation was established in 1989 to promote research to find a cure for oxalosis, primary hyperoxaluria, and related kidney stone diseases and improve the care and treatment of those affected. To date, the foundation has provided more than $10 million dollars for PH-related education, awareness, and research programs.

One of the PKD Foundation's principal goals is the development of clinical interventions for the treatment of polycystic kidney disease. Under this RFA, proposals in the following areas will be accepted:   Basic laboratory research aimed at increasing understanding of the genetic and pathological processes involved in PKD Research with an obvious or direct potential to accelerate the development of potential therapies

The Stimulating Hematology Investigation:New Endeavors (SHINE) program is intended to promote innovative, high quality hematology research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).In the SHINE program, NIDDK invites investigator-initiated research project grant applications in specific areas of basic and translational hematology research where needs and opportunities for progress are particularly timely.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)s Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) conducts multi-site, multi-disciplinary studies of Lower Urinary Tract Dysfunction (LUTD) to better define clinical phenotype, to better describe the impact and diversity of symptoms, and to develop new patient-centric tools for improved measurement of clinical symptoms, all with the goals of informing future clinical studies and improving patient care. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to solicit applications from the current LURN Data Coordinating Center for a second five-year Project Period.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)s Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) conducts multi-site, multi-disciplinary studies of Lower Urinary Tract Dysfunction (LUTD) to better define clinical phenotype, to better describe the impact and diversity of symptoms, and to develop new patient-centric tools for improved measurement of clinical symptoms, all with the goals of informing future clinical studies and improving patient care. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite applications from current LURN Research Sites for a second five-year Project Period.

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for New Investigators from backgrounds nationally underrepresented in biomedical and behavioral research to conduct small research projects in the scientific mission areas of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The R21 is intended to support small research projects that can be carried out in a short period of time with limited resources and seeks to facilitate the transition to research independence of New Investigators from backgrounds underrepresented in the biomedical and behavioral sciences. The R21 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

This Funding Opportunity Announcement (FOA) seeks to stimulate HIV/AIDS research within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) that addresses high priority HIV/AIDS research priorities outlined by the NIH Office of AIDS Research (OAR). These priorities are described in NOT-OD-15-137: NIH HIV/AIDS Research Priorities and Guidelines for Determining AIDS Funding.

This Funding Opportunity Announcement (FOA) is calling for R01 grant applications in nonmalignant hematology research. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build and promote research activities in nonmalignant hematology. Innovative research project applications that will steer the field in new directions are invited. Each project will propose proof of principle research that is tightly focused into one specific aim and is directed at validating novel concepts and approaches that promise to open up new pathways for discovery. Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications.

The prevalence of obesity is increasing in people with HIV (PWH), contributing to multiple complications associated with this condition. There is mounting evidence that unique mechanisms contribute to the development of obesity in PWH versus people without HIV. Alterations in fat tissue biology may be central to these differences. This FOA seeks applications to elucidate the underlying mechanisms of how HIV and antiretroviral drugs used for therapy or pre-exposure prophylaxis contribute to the development of obesity and alter adipocyte and adipose tissue function as well as the effects of these processes on metabolic and physiological processes within the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

This Funding Opportunity Announcement (FOA) invites applications for innovative basic and translational research projects examining HIV infection, persistence, and comorbidities as they relate to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and consistent with the scientific priorities outlined by the NIH Office of AIDS Research (OAR) in NOT-OD-15-137.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) announces a program that provides NIDDK-supported K01, K08, K23, and K25 recipients the opportunity to apply for Small Grant (R03) support at some point during the latter years of their award period of their K award. Through the use of this mechanism, the NIDDK is seeking to enhance the capability of its K01, K08, K23, and K25 award recipients to conduct research as they complete their transition to fully independent investigator status. The R03 grant mechanism supports different types of projects, including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. The R03 is, therefore, intended to support research projects that can be carried out in a short period of time with limited resources and that may provide preliminary data to support a subsequent R01, or equivalent, application.